Propanc Biopharma raises ~$61k via two convertible notes with dilutive terms

Propanc Biopharma, Inc.

Dec 16 note: $22k principal ($20k proceeds), 8% interest, matures June 15, 2025; convertible at $0.0003/share (step-down to $0.0001).
Dec 20 note: $49.2k principal ($41k proceeds), 15% one-time interest, due Oct 15, 2025; conversion at 65% of lowest 10-day trading price.
Proceeds used for general working capital; notes are private placements under Rule 506.
Note terms include 4.99% beneficial ownership cap and prepayment premiums up to 125% face value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.